NCT02263378 is a NA clinical trial of ellagic acid + annona muricata in HPV Infection, sponsored by University of Messina.

Who is sponsoring NCT02263378?

NCT02263378 is sponsored by University of Messina.

What drugs are being tested in NCT02263378?

Interventions in NCT02263378: ellagic acid + annona muricata.

What condition does NCT02263378 study?

NCT02263378 studies HPV Infection.

Is NCT02263378 still recruiting?

NCT02263378 is currently completed. Last updated 23 May 2016.

Last reviewed 2016-05-23 · How we verify

NCT02263378

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ellagic Acid and Annona Muricata May Modulate the Immune Response to High Risk HPV Infection. A Randomized, Controlled Trial.

Completed NA Last updated 23 May 2016

What this trial tests

NA trial testing ellagic acid + annona muricata in HPV Infection in 60 participants. Completed in 1 March 2016.

Timeline

1 September 2014

Primary endpoint
1 March 2016

1 March 2016

Quick facts

Lead sponsor	University of Messina
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	1 September 2014
Primary completion	1 March 2016
Estimated completion	1 March 2016

Drugs / interventions tested

ellagic acid + annona muricata — full drug profile →

Conditions studied

HPV Infection — all drugs for HPV Infection →

Sponsor

University of Messina

Who can join

Adults 20 to 50, female only, with HPV Infection. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

variation of onco suppressor protein expression from basal values. The expression variations are represented by the different percentage of positive cells
Time frame: 6 months

Sponsor's own description

The purpose of this study is to evaluate whether a supplement in which ellagic acid plus annona muricata are combined, may modulate the immune response to high risk HPV infection. Sixty women will be enrolled in a randomized, controlled study, having a histological diagnosis of L-SIL correlated with high rish HPV types infection. Main outcome measure is the activation of onco suppressor protein by the supplement and secondary outcome is the clearance of HPV infection in the treated group.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for HPV Infection

Currently open trials in the same condition.

NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
NCT07281677 — Immunogenicity and Safety of Sequential 2vHPV-9vHPV Vaccination in Girls Aged 9-14 Years · Phase 4 · recruiting
NCT06507917 — Concordance and Acceptability of Self-screening Versus Screening by a Healthcare Professional for HPV, a Risk Factor for · NA · recruiting
NCT07336134 — PopSci CHW4CervixHealth · NA · recruiting
NCT06959563 — Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating HPV · EARLY_PHASE1 · active not recruiting

Other University of Messina trials

Trials by the same sponsor.

NCT07106463 — Microbiota: Its Role in Chronic Inflammation, IDB and Risk of Colorectal Cancer. Evaluation of a Predictive Prognostic M · active not recruiting
NCT05496322 — Continuous Vs Intermittent Non Invasive Blood Pressure Monitoring in Preventing Post Operative Organ Failure · NA · completed
NCT05122741 — Modulation of Fibrosis-inducing Pathways in Acute Myocardial Infarction · unknown
NCT04994379 — Investigating the Effects of Intensity of Transcranial Direct Current Stimulation on Subjective Appetite · NA · terminated
NCT06787781 — Metabolic and Clinical Effect of Alpha-lipoic Acid Administration in Schizophrenic Subjects · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02263378 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Messina
Last refreshed: 23 May 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02263378.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing